Aktis Oncology (NASDAQ:AKTS - Get Free Report) Director Ken Herrmann sold 4,856 shares of the business's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $24.56, for a total transaction of $119,263.36. Following the sale, the director directly owned 3,506 shares in the company, valued at $86,107.36. The trade was a 58.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Aktis Oncology Trading Down 5.1%
NASDAQ:AKTS opened at $22.97 on Wednesday. Aktis Oncology has a 1 year low of $14.72 and a 1 year high of $34.19. The stock's fifty day moving average is $24.07. The stock has a market capitalization of $1.23 billion and a P/E ratio of -60.45.
Aktis Oncology (NASDAQ:AKTS - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The firm had revenue of $3.23 million during the quarter, compared to the consensus estimate of $2.23 million. Equities analysts forecast that Aktis Oncology will post -1.64 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on AKTS shares. HC Wainwright lifted their target price on Aktis Oncology from $33.00 to $35.00 and gave the company a "buy" rating in a report on Tuesday, June 2nd. Wall Street Zen lowered shares of Aktis Oncology from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings raised shares of Aktis Oncology from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. upped their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Tuesday, July 14th. Finally, Raymond James Financial started coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They issued a "strong-buy" rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.60.
Check Out Our Latest Research Report on Aktis Oncology
About Aktis Oncology
(
Get Free Report)
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
